GLG CEO Survey 2022 Released: Findings include CEO investment plans, concerns, and a forecast for the year ahead.

All Insights

GLG’s approximately 1 million Network Members include thought leaders across every major sector and geography. Hear from some of them below.

Biogen’s Aduhelm: An Update on the Commercial Rollout
Article

Biogen’s Aduhelm: An Update on the Commercial Rollout

FDA’s Controversial Aduhelm Approval: What Happens Next?
Article

FDA’s Controversial Aduhelm Approval: What Happens Next?

Subscribe to Insights 360

Enter your email below and receive our monthly newsletter, featuring insights from GLG’s network of approximately 1 million professionals with first-hand expertise in every industry.